Other Events ·
MoonLake Immunotherapeutics held its 2026 Annual General Meeting of Shareholders on June 4, 2026, where shareholders…
MLTXMoonLake Immunotherapeutics
MoonLake Immunotherapeutics held its 2026 Annual General Meeting of Shareholders on June 4, 2026, where shareholders approved an amendment and restatement of the 2022 Equity Incentive Plan to increase the number of available Class A Ordinary Shares for stock-based awards by 5,000,000 shares. The meeting also resulted in the election of Spike Loy as a Class I director nominee and the election of Baker Tilly US, LLP as independent auditor. MoonLake Immunotherapeutics is a biotechnology company focused on developing immunological and immunological-related therapies.